IP Library Granted Patent US 10,927,068
Granted Patent B2
US 10,927,068 · App. 16/201,645 · Granted Feb 23, 2021

Process for preparing acylated amphetamine derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,927,068
App. No.
16/201,645
Granted
Feb 23, 2021
Kind
B2
Abstract

Processes for preparing acetylated amphetamine derivatives and, in particular, processes for preparing L -lysine- D -amphetamine dimesylate from D -amphetamine salts.

Claims (30)

1. A process for preparing a compound of Formula (IV), the process comprising:

(a) forming a reaction mixture comprising a solvent and a compound of Formula (I), the solvent being an alkyl tetrahydrofuran;

(b) adding a compound of Formula (II) to the reaction mixture, thereby forming an intermediate compound of Formula (III);

(c) phase extracting the reaction mixture after step (b) with (i) a water wash; (ii) an acid wash having a pH of <3.0, (iii) an alkaline wash having a pH of >12.0, and (iv) one or more additional water washes to remove the compounds of Formulas (I) and (II) and reaction by-products, thereby forming a purified mixture comprising the intermediate compound of Formula (III); and

(d) contacting the purified mixture comprising the intermediate compound of Formula (III) with an acid to form the compound of Formula (IV);

wherein:

R is hydrocarbyl or substituted hydrocarbyl;

LG is a leaving group chosen from N-hydroxysuccinimidyl or halo;

PG is a protecting group; and

A is an anion.

2. The process of claim 1 , wherein R is an amino acid side chain chosen from —(CH 2 ) 4 —NH 2 , —(CH 2 ) 3 —NH—C(NH)—NH 2 , —(CH 2 ) 4 —NH—C(NH)—NH 2 , —CH 2 —C(O)—NH 2 , —(CH 2 ) 2 —C(O)—NH 2 , —CH 2 —SH, —CH 2 —OH, CH(OH)—CH 3 , —CH 2 -Ph-OH, —CH2-C(O)—OH, or —(CH 2 ) 2 —C(O)—OH; and PG is tert-butyloxycarbonyl, triphenylmethyl, dimethyl-3,5-dimetheoxybenzyloxycarbonyl, 2-(4-biphenyl)isopropoxycarbonyl, 2-nitropheylsulfenyl, 2-chlorobenzyloxycarbonyl, or 4-methyltriphenymethyl.

3. The process of claim 1 , wherein the alkyl tetrahydrofuran and the compound of Formula (I) are present in the reaction mixture at a weight ratio of about 5:1 to about 15:1; steps (b) and (c) are conducted at room temperature; the acid at step (d) is methanesulfonic acid, hydrochloric acid, or oxalic acid; and step (d) is conducted at a temperature from about 40° C. to about 70° C.

4. The process of claim 1 , further comprising azeotropically drying the purified mixture comprising the intermediate compound of Formula (III) after step (c) until it has a water content of less than about 2% by weight.

5. The process of claim 1 , further comprising isolating the compound of Formula (IV) after step (d) by filtration.

6. The process of claim 5 , further comprising recrystallizing the compound of Formula (IV).

7. The process of claim 1 , wherein the compound of Formula (I) is a compound of Formula (Ia):

the compound of Formula (II) is a compound of Formula (IIa):

the intermediate compound of Formula (III) is a compound of Formula (IIIa),

and

the compound of Formula (IV) is a compound of Formula (IVa):

8. The process of claim 7 , wherein the alkyl tetrahydrofuran at step (a) is 2-methyl tetrahydrofuran.

9. The process of claim 8 , wherein 2-methyl tetrahydrofuran and the compound of Formula (Ia) are present in the reaction mixture at a weight ratio of about 6:1 to about 10:1.

10. The process of claim 9 , wherein the compound of Formula (IIa) is prepared from a salt of a compound of Formula (IIa) by contacting the salt of the compound of Formula (IIa) with an alkali metal or alkaline earth metal hydroxide, followed by one or more extractions with 2-methyl tetrahydrofuran.

11. The process of claim 7 , wherein steps (a) and (b) are conducted at room temperature; and step (d) is conducted at a temperature from about 50° C. to about 60° C.

12. The process of claim 7 , wherein step (c) comprises sequential contact with a water solution, a solution of hydrochloric acid having a pH of less than about 3, a solution of sodium hydroxide having a pH of greater than about 12, and one or more additional water solutions.

13. The process claim 7 , further comprising azeotropically drying the purified mixture comprising the intermediate compound of Formula (IIIa) after step (c) until it has a water content of less than about 1% by weight.

14. The process of claim 7 , further comprising isolating the compound of Formula (IVa) by filtration after step (d).

15. The process of claim 14 , further comprising recrystallizing the compound of Formula (IVa).

16. The process of claim 15 , wherein the recrystallizing is conducted in the presence of a mixture of isopropanol and water.

17. The process of claim 15 , further comprising washing the crystallized compound of Formula (IVa) with isopropanol.

Assignments (12)
RELEASE OF SECURITY INTEREST Recorded Aug 14, 2025
From: ACQUIOM AGENCY SERVICES LLC
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
Reel/Frame 072324/0740 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 31, 2025
From: SPECGX LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS COLLATERAL AGENT
Reel/Frame 072313/0063 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 060434, FRAME 0536 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; VTESSE LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; SUCAMPO PHARMA AMERICAS LLC
Reel/Frame 065601/0347 →
RELEASE OF PATENT SECURITY INTERESTS RECORDED AT REEL 049823, FRAME 0233 Recorded Nov 16, 2023
From: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
To: MALLINCKRODT INTERNATIONAL FINANCE S.A.; MALLINCKRODT CB LLC; MALLINCKRODT FINANCE GMBH; MALLINCKRODT US HOLDINGS LLC (F/K/A MALLINCKRODT US HOLDINGS INC.); MALLINCKRODT CARRIBEAN, INC.; MALLINCKRODT US POOL LLC; MNK 2011 LLC (F/K/A MALLINCKRODT INC.); LUDLOW LLC (F/K/A LUDLOW CORPORATION); CNS THERAPEUTICS, INC.; MALLINCKRODT ENTERPRISES HOLDINGS LLC (F/K/A MALLINCKRODT ENTERPRISES HOLDINGS, INC.); MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; LAFAYETTE PHARMACEUTICALS LLC; LIEBEL-FLARSHEIM COMPANY LLC; MALLINCKRODT BRAND PHARMACEUTICALS LLC (F/K/A MALLINCKRODT BRAND PHARMACEUTICALS, INC.); MALLINCKRODT VETERINARY, INC.; MALLINCKRODT US HOLDINGS LLC; IMC EXPLORATION COMPANY; MEH, INC.; MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC (F/K/A VTESSE INC.); MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING D.A.C.); INFACARE PHARMACEUTICAL CORPORATION; ST SHARED SERVICES LLC; THERAKOS, INC.; IKARIA THERAPEUTICS LLC; INO THERAPEUTICS LLC
Reel/Frame 065609/0629 →
SECURITY INTEREST Recorded Nov 15, 2023
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; OCERA THERAPEUTICS LLC; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC
To: ACQUIOM AGENCY SERVICES LLC
Reel/Frame 065595/0376 →
RELEASE OF SECURITY INTERESTS IN PATENTS AT REEL 060389/FRAME 0913 Recorded Nov 15, 2023
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS LLC (F/K/A OCERA THERAPEUTICS, INC.); MALLINCKRODT LLC; MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY; SPECGX LLC; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 065583/0465 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jun 22, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED; MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY
To: DEUTSCHE BANK AG NEW YORK BRANCH
Reel/Frame 060434/0536 →
RELEASE OF SECURITY INTEREST Recorded Jun 17, 2022
From: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
To: OCERA THERAPEUTICS, INC.; MALLINCKRODT LLC; MALLINCKRODT ARD IP UNLIMITED COMPANY (F/K/A MALLINCKRODT ARD IP LIMITED); MALLINCKRODT HOSPITAL PRODUCTS IP UNLIMITED COMPANY (F/K/A MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED); MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY (F/K/A MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY); SPECGX LLC; STRATATECH CORPORATION; VTESSE LLC (F/K/A VTESSE INC.)
Reel/Frame 060389/0839 →
SECURITY INTEREST Recorded Jun 17, 2022
From: MALLINCKRODT ENTERPRISES LLC; MALLINCKRODT LLC; SPECGX LLC; OCERA THERAPEUTICS, INC.; STRATATECH CORPORATION; SUCAMPO PHARMA AMERICAS LLC; VTESSE LLC; MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 060389/0913 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 7, 2020
From: ORR, BRIAN; ROESCH, KEVIN; MCCLENAGHAN, JOEL
To: SPECGX LLC
Reel/Frame 053998/0444 →
SECURITY INTEREST Recorded Dec 10, 2019
From: MALLINCKRODT ARD IP LIMITED; MALLINCKRODT HOSPITAL PRODUCTS IP LIMITED; SPECGX LLC; OCERA THERAPEUTICS, INC.; MALLINCKRODT PHARMA IP TRADING DESIGNATED ACTIVITY COMPANY; STRATATECH CORPORATION; VTESSE INC.; MALLINCKRODT LLC
To: WILMINGTON SAVINGS FUND SOCIETY, FSB, AS SECOND LIEN COLLATERAL AGENT
Reel/Frame 051256/0829 →
NOTICE OF GRANT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jul 22, 2019
From: SPECGX LLC
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 049823/0233 →